Recently, a novel scoring system derived from Gender, Age, AFP-L3, AFP, and DCP, named GALAD, was established for the detection of HCC in patients with chronic liver disease (Johnson et al. 2014). This evidence concerns the gene AFP and hepatocellular carcinoma.